SEC FORM 3

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Crombez Eric

(Last)

(First)

(Middle)

C/O ULTRAGENYX PHARMACEUTICAL INC.

60 LEVERONI COURT

(Street)

NOVATO

94949

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
05/01/2023

3. Issuer Name and Ticker or Trading Symbol
Ultragenyx Pharmaceutical Inc. [ RARE ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP and Chief Medical Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	25,854⁽¹⁾	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (Right to Buy)	⁽²⁾	11/17/2027	Common Stock	7,500	$48.11	D
Stock Option (Right to Buy)	⁽³⁾	03/01/2029	Common Stock	8,000	$67.55	D
Stock Option (Right to Buy)	⁽⁴⁾	03/01/2030	Common Stock	13,000	$56.08	D
Stock Option (Right to Buy)	⁽⁵⁾	03/01/2031	Common Stock	4,310	$142.47	D
Stock Option (Right to Buy)	⁽⁶⁾	03/01/2032	Common Stock	6,335	$67.37	D
Stock Option (Right to Buy)	⁽⁷⁾	03/01/2033	Common Stock	9,845	$45.65	D

Explanation of Responses:

1. Includes 12,601 Restricted Stock Units ("RSUs") awarded under the Company's 2014 Incentive Plan. The RSUs vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date. Of the 12,601 RSUs, 1,115 RSUs were granted on March 1, 2020, 720 RSUs were granted on March 1, 2021, 1,000 RSUs were granted on April 16, 2021, 2,381 RSUs were granted on March 1, 2022 and 7,385 RSUs were granted on March 1, 2023.

2. 1/4th of the shares initially subject to the option vested on November 17, 2018; thereafter, 1/48th of the shares initially subject to the option vested monthly.

3. 1/4th of the shares initially subject to the option vested on March 1, 2020; thereafter, 1/48th of the shares initially subject to the option vested monthly.

4. 1/4th of the shares initially subject to the option vested on March 1, 2021 thereafter, 1/48th of the shares initially subject to the option shall vest monthly.

5. 1/4th of the shares initially subject to the option vested on March 1, 2022 thereafter, 1/48th of the shares initially subject to the option shall vest monthly.

6. 1/4th of the shares initially subject to the option vested on March 1, 2023 thereafter, 1/48th of the shares initially subject to the option shall vest monthly.

7. 1/4th of the shares initially subject to the option will vest on March 1, 2024 thereafter, 1/48th of the shares initially subject to the option shall vest monthly.

Remarks:

	/s/ Karah Parschauer, attorney-in-fact	05/02/2023
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.